The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...

The drugmaker is looking to its oncology pipeline to drive its next leg of growth.

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

The ASX biotech sector lost about 7% of its value in May. But not every stock lagged and hopes for a rebound abound.

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare ...

On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.